There are 203 resources available
Q&A and discussion
Session: MAPkinase
Resources:
Webcast
40O - Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
Presenter: Emiliano Calvo
Session: Oral abstract session 2
Resources:
Abstract
Slides
Webcast
9O - Phase I/II, open-label, first-in-human study of the anti-GPC3 T cell engager SAR444200 in patients with advanced solid tumors: Updated safety and pharmacokinetic analysis
Presenter: Khaldoun Almhanna
Session: Oral abstract session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant 40O and 9O
Presenter: Valentina Boni
Session: Oral abstract session 2
Resources:
Slides
Webcast
Q&A and discussion
Session: Oral abstract session 2
Resources:
Webcast
22O - Development of anti-CD38-CAR allogeneic γδ T cells as an off-the-shelf use for myeloma
Presenter: Yuji Hattori
Session: Oral abstract session 2
Resources:
Abstract
Slides
Webcast
10O - First-in-human, dose escalation of MT-8421: A novel engineered toxin body (ETB) targeting CTLA-4, in patients with select advanced solid tumors
Presenter: Justin Moyers
Session: Oral abstract session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant 22O and 10O
Presenter: Eytan Stein
Session: Oral abstract session 2
Resources:
Slides
Webcast
Q&A and discussion
Session: Oral abstract session 2
Resources:
Webcast
How do we pick a recommended dose: Safe may be, but optimised?
Presenter: Elena Garralda
Session: Workshop in collaboration with ESMO YOC: Evaluation of phase I data at the end of the study for next planning of drug development
Resources:
Slides
Webcast